Following HIV diagnosis, linkage to outpatient treatment, antiretroviral initiation, and longitudinal retention in care represent the foundation for successful treatment. While prior studies have evaluated these processes in isolation, a systematic evaluation of successive steps in the same cohort of patients has not yet been performed. To ensure optimal long-term outcomes, a better understanding of the interplay of these processes is needed. Therefore, a retrospective cohort study of patients initiating outpatient care at the University of Alabama at Birmingham 1917 HIV=AIDS Clinic between January 2000 and December 2005 was undertaken. Multivariable models determined factors associated with: late diagnosis=linkage to care (initial CD4 < 350 cells=mm3), timely antiretroviral initiation, and retention across the first two years of care. Delayed linkage was observed in two-thirds of the overall sample (n = 567) and was associated with older age (odds ratio [OR] = 1.31 per 10 years; 95%confidence interval [CI] = 1.06-1.62) and African American race (OR = 2.45; 95% CI = 1.60-3.74). Attending all clinic visits (hazard ratio [HR] = 6.45; 95% CI = 4.47-9.31) and lower initial CD4 counts led to earlier antiretroviral initiation. Worse retention in the first 2 years was associated with younger age (OR = 0.68 per 10 years;95% CI = 0.56-0.83), higher baseline CD4 count, and substance abuse (OR = 1.78; 95% CI = 1.16-2.73). Interventions to improve timely HIV diagnosis and linkage to care should focus on older patients and African Americans while efforts to improve retention should address younger patients, those with higher baseline CD4 counts, and substance abuse. Missed clinic visits represent an important obstacle to the timely initiation of antiretroviral therapy. These data inform development of interventions to improve linkage and retention in HIV care, an emerging area of growing importance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733237 | PMC |
http://dx.doi.org/10.1089/apc.2008.0132 | DOI Listing |
PLoS One
January 2025
Departments of Public Health, Institute of Health Sciences, Wollega University, Ethiopia.
Introduction: The mortality rate among Human immunodeficiency Virus (HIV) who have started antiretroviral therapy (ART) continues to be increased in resource-limited countries, despite a decline in developed nations. Furthermore, research within this age group is limited and has not previously been conducted in the study area. Consequently, this study aimed to determine the incidence of mortality and its predictors among HIV-positive children who have been receiving ART at public health facilities in West Wollega.
View Article and Find Full Text PDFCells
January 2025
Department of Oncology (Medical Oncology), Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Kaposi Sarcoma (KS) is a vascular tumor originating from endothelial cells and is associated with human herpesvirus 8 (KSHV) infection. It disproportionately affects populations facing health disparities. Although antiretroviral therapy (ART) has improved KS control in people with HIV (PWH), treatment options for advanced KS remain limited.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Statistics, College of Natural and Computational Science, Debre Tabor University, Debre Tabor, Ethiopia.
The human immunodeficiency virus systematically undermines the immune system, which serves as our body's inherent safeguard against diseases. Currently, it is the most serious threat to public health. Ethiopia is among the countries with the highest prevalence of HIV/AIDS.
View Article and Find Full Text PDFBMJ Glob Health
January 2025
School of Public Health, Makerere University, Kampala, Uganda.
Introduction: In Uganda, fisherfolk have an HIV prevalence between 15% and 40%, significantly higher than the national average of 5.5%. Pre-exposure prophylaxis (PrEP) is effective in preventing HIV but faces challenges in uptake and continuation among fisherfolk.
View Article and Find Full Text PDFAfr J Prim Health Care Fam Med
December 2024
School of Public Health, Faculty of Community and Health Sciences, University of the Western Cape, Cape Town.
Background: Oral pre-exposure prophylaxis (PrEP) uses antiretroviral medication to reduce HIV risk in HIV-negative individuals. Despite its effectiveness, global uptake faces policy and accessibility challenges. In Eswatini, PrEP introduction in 2017 showed promise despite stigma and COVID-19 disruptions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!